Six-hundred thousand to eight-hundred thousand Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy. This group accounts for around 40 per cent of all diabetics. Researchers at the University Departments of General Medicine II and III at the MedUni Vienna have now demonstrated that high-dose, personalised therapy with ACE inhibitors and beta blockers can significantly reduce the risk of cardiac disease among affected patients – by as much as 64 per cent.
Three hundred patients with diabetes mellitus and elevated NT-proBNP levels who had no history of heart disease took part in the Pontiac study, the results of which have now been published in the top journal Journal of the American College of Cardiology. The study, which was carried out in collaboration with the MedUni Vienna's Clinical Department of Endocrinology and Metabolic Medicine and Clinical Department of Cardiology, along with the 3rd Department of Medicine at Hietzing Hospital and the health centres in central and south Vienna, involved 150 patients who were randomised to the intervention group and 150 patients who were randomised to the control group.
"In the intervention group, in addition to the diabetes treatment being given in accordance with treatment guidelines, RAAS antagonists that were already being prescribed were increased to the maximum permitted dose, while at the same time patients were given the maximum possible dose of a cardioselective beta blocker," explains Martin Clodi from the University Department of General Medicine III at the MedUni Vienna, who, together with Richard Pacher and Martin Hülsmann (General Medicine II), is one of the senior authors of the study. The 150 patients in the control group were given treatment that complies with the currently applicable guidelines set down by the Austrian Diabetes Society.
The striking result was that, in the intervention group, it was demonstrated that high-dose RAAS antagonists, in combination with beta blockers, can reduce the risk of cardiovascular events by 64 percent. "The results strongly indicate, with all due safety considerations, the excellent effectiveness of biomarker-led, personalised therapy," says Clodi, and Pacher adds: "This is the first primary preventative study approach for the successful prophylaxis of cardiac disease in diabetics".
Explore further: Diabetes mellitus and the life-threatening late complications of cardivascular disease
More information: Huelsmann, M. et al. PONTIAC: NT-proBNP selected Prevention of cardiac events in a population of diabetic patients without a history of Cardiac disease. A prospective randomized controlled trial, J Am Coll Cardiol, 2013 Jun 26. pii: S0735-1097(13)02517-5. DOI: 10.1016/j.jacc.2013.05.069 . PMID: 23810874
Medical Xpress on facebook
Related Stories
Diabetes mellitus and the life-threatening late complications of cardivascular disease
Nov 14, 2012
Between 600,000 and 800,000 Austrians have diabetes mellitus. This "sugar disease", as it is known, can itself already be treated very effectively. The later consequences of diabetes, however, which mostly ...
One cause of fatty deposits in the hearts of diabetes patients settled
Apr 16, 2012
The impaired substrate metabolism of diabetes patients is often expressed in an increase in fatty deposits in the cells of the heart muscle. Until now, the exact cause of this was unknown. Now, Austrian researchers ...
Life without fits: New treatment for refractory epilepsies
Sep 18, 2013
Through a joint project between the University Departments of Neurology and Neurosurgery at the MedUni Vienna, a new treatment option has recently been launched that promises people with difficult-to-treat ...
More diseases responsible for dementia than previously thought, research finds
Sep 19, 2013
A recent study by the Clinical Institute of Neurology at the MedUni Vienna has shown that neurodegenerative diseases other than Alzheimer's disease are more common among older people than previously thought. ...
Gout drug shown to benefit diabetes patients at risk of heart disease
Aug 29, 2013
New research carried out at the University of Dundee has led to the possibility of using an old drug to help prevent the biggest cause of death in Type II diabetes patients.
Recommended for you
Health-care providers should aggressively treat unhealthy lifestyles
16 hours ago
Healthcare providers should treat unhealthy behaviors as aggressively as they treat high blood pressure, cholesterol and other heart disease risk factors, according to an American Heart Association policy statement published ...
Pediatric atrial fibrillation, rare, but has serious complications risk and high recurrence rates
18 hours ago
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated ...
Team designing new drug for common heart condition
18 hours ago
An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a common heart-rhythm ...
Risk factors for MACE following noncardiac surgery for patients with coronary stents
20 hours ago
Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA. The st ...
Air pollution increases heart attacks
Oct 07, 2013
Air pollution increases heart attacks, according to research presented at the Acute Cardiac Care Congress 2013 by Dr Savina Nodari from Brescia, Italy. The Acute Cardiac Care Congress 2013 is the annual meeting of the Acute ...
Silencing sudden death: Study targets genetics of hypertrophic cardiomyopathy
Oct 03, 2013
Hypertrophic cardiomyopathy (HCM), a disease in which cardiac muscle thickens, weakening the heart, can be prevented from developing for several months in mice by reducing production of a mutant protein, according to a new ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Six-hundred thousand to eight-hundred thousand Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular disease can be determined even though their hearts appear to be healthy. This group accounts for around 40 per cent of all diabetics. Researchers at the University Departments of General Medicine II and III at the MedUni Vienna have now demonstrated that high-dose, personalised therapy with ACE inhibitors and beta blockers can significantly reduce the risk of cardiac disease among affected patients – by as much as 64 per cent.
Three hundred patients with diabetes mellitus and elevated NT-proBNP levels who had no history of heart disease took part in the Pontiac study, the results of which have now been published in the top journal Journal of the American College of Cardiology. The study, which was carried out in collaboration with the MedUni Vienna's Clinical Department of Endocrinology and Metabolic Medicine and Clinical Department of Cardiology, along with the 3rd Department of Medicine at Hietzing Hospital and the health centres in central and south Vienna, involved 150 patients who were randomised to the intervention group and 150 patients who were randomised to the control group.
"In the intervention group, in addition to the diabetes treatment being given in accordance with treatment guidelines, RAAS antagonists that were already being prescribed were increased to the maximum permitted dose, while at the same time patients were given the maximum possible dose of a cardioselective beta blocker," explains Martin Clodi from the University Department of General Medicine III at the MedUni Vienna, who, together with Richard Pacher and Martin Hülsmann (General Medicine II), is one of the senior authors of the study. The 150 patients in the control group were given treatment that complies with the currently applicable guidelines set down by the Austrian Diabetes Society.
The striking result was that, in the intervention group, it was demonstrated that high-dose RAAS antagonists, in combination with beta blockers, can reduce the risk of cardiovascular events by 64 percent. "The results strongly indicate, with all due safety considerations, the excellent effectiveness of biomarker-led, personalised therapy," says Clodi, and Pacher adds: "This is the first primary preventative study approach for the successful prophylaxis of cardiac disease in diabetics".
Explore further: Diabetes mellitus and the life-threatening late complications of cardivascular disease
More information: Huelsmann, M. et al. PONTIAC: NT-proBNP selected Prevention of cardiac events in a population of diabetic patients without a history of Cardiac disease. A prospective randomized controlled trial, J Am Coll Cardiol, 2013 Jun 26. pii: S0735-1097(13)02517-5. DOI: 10.1016/j.jacc.2013.05.069 . PMID: 23810874
Medical Xpress on facebook
Related Stories
Diabetes mellitus and the life-threatening late complications of cardivascular disease
Nov 14, 2012
Between 600,000 and 800,000 Austrians have diabetes mellitus. This "sugar disease", as it is known, can itself already be treated very effectively. The later consequences of diabetes, however, which mostly ...
One cause of fatty deposits in the hearts of diabetes patients settled
Apr 16, 2012
The impaired substrate metabolism of diabetes patients is often expressed in an increase in fatty deposits in the cells of the heart muscle. Until now, the exact cause of this was unknown. Now, Austrian researchers ...
Life without fits: New treatment for refractory epilepsies
Sep 18, 2013
Through a joint project between the University Departments of Neurology and Neurosurgery at the MedUni Vienna, a new treatment option has recently been launched that promises people with difficult-to-treat ...
More diseases responsible for dementia than previously thought, research finds
Sep 19, 2013
A recent study by the Clinical Institute of Neurology at the MedUni Vienna has shown that neurodegenerative diseases other than Alzheimer's disease are more common among older people than previously thought. ...
Gout drug shown to benefit diabetes patients at risk of heart disease
Aug 29, 2013
New research carried out at the University of Dundee has led to the possibility of using an old drug to help prevent the biggest cause of death in Type II diabetes patients.
Recommended for you
Health-care providers should aggressively treat unhealthy lifestyles
16 hours ago
Healthcare providers should treat unhealthy behaviors as aggressively as they treat high blood pressure, cholesterol and other heart disease risk factors, according to an American Heart Association policy statement published ...
Pediatric atrial fibrillation, rare, but has serious complications risk and high recurrence rates
18 hours ago
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated ...
Team designing new drug for common heart condition
18 hours ago
An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a common heart-rhythm ...
Risk factors for MACE following noncardiac surgery for patients with coronary stents
20 hours ago
Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA. The st ...
Air pollution increases heart attacks
Oct 07, 2013
Air pollution increases heart attacks, according to research presented at the Acute Cardiac Care Congress 2013 by Dr Savina Nodari from Brescia, Italy. The Acute Cardiac Care Congress 2013 is the annual meeting of the Acute ...
Silencing sudden death: Study targets genetics of hypertrophic cardiomyopathy
Oct 03, 2013
Hypertrophic cardiomyopathy (HCM), a disease in which cardiac muscle thickens, weakening the heart, can be prevented from developing for several months in mice by reducing production of a mutant protein, according to a new ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment